The artificial blood vessel product independently developed by Jiangxi Covipeptide Biotechnology, a holding subsidiary of Sanxin Medical, has received approval from the National Medical Products Administration to enter the special review procedure for innovative medical devices. The product uses an integrated expanded polytetrafluoroethylene material, featuring puncture resistance without delamination and excellent biocompatibility. The technological achievement has been listed by the Zhejiang Provincial Department of Science and Technology as one of the major scientific and technological achievements of 2025. After entering this procedure, the product registration application will enjoy priority processing benefits. In the first quarter of 2026, Sanxin Medical achieved revenue of 409 million yuan and a net profit attributable to the parent company of 68.36 million yuan.
Jiangxi Sanxin Medtec Co LtdSubsidiary's artificial blood vessel product enters special review for innovative medical devices, a positive regulatory milestone.